Microbix Biosystems Inc.
MBXBF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -7.27 | 0.16 | 0.34 |
| FCF Yield | -5.06% | 1.22% | 1.05% | 1.15% |
| EV / EBITDA | -37.19 | 71.38 | 32.48 | 32.72 |
| Quality | ||||
| ROIC | -3.69% | 0.49% | 2.72% | 0.00% |
| Gross Margin | 40.75% | 59.50% | 62.09% | 54.82% |
| Cash Conversion Ratio | 1.17 | 46.78 | 0.93 | 1.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.43% | 12.26% | 11.26% | 10.01% |
| Free Cash Flow Growth | -393.62% | 22.35% | 9.92% | 33.83% |
| Safety | ||||
| Net Debt / EBITDA | 5.85 | -13.13 | -4.34 | -5.38 |
| Interest Coverage | -5.91 | 0.71 | 4.20 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.23 | 0.26 | 0.32 | 0.44 |
| Cash Conversion Cycle | 449.70 | 306.76 | 245.50 | 180.23 |